Patents Assigned to Octapharma AG
  • Publication number: 20170051028
    Abstract: A process of purifying a Growth Factor Protein in a purification sequence employing chromatography characterized in that at least one chromatography is performed using a multimodal resin the Growth Factor Protein binds to the multimodal resin at a pH between 4 to 6.2, and the Growth Factor Protein is eluting at a pH >6.3, and the elution of Growth Factor Protein is improved by addition of arginine and/or NaCl to the eluting buffer. The multimodal resin step is followed by a yeast derived affinity ligand resin step, which results of a purity of the product >90%.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 23, 2017
    Applicant: OCTAPHARMA AG
    Inventors: Gustav Gilljam, Stefan Winge, Maya Tiemeyer
  • Patent number: 9512457
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: December 6, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Publication number: 20160340410
    Abstract: A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
    Type: Application
    Filed: January 20, 2015
    Publication date: November 24, 2016
    Applicant: OCTAPHARMA AG
    Inventors: Stefan Winge, Marina Dadaian, Erica Johansson, Birte Fuchs
  • Patent number: 9453045
    Abstract: A process of purifying the Growth Factor Protein G-CSF (Granulocyte Colony Stimulating Factor) in a purification sequence employing chromatography, comprising binding the G-CSF to Capto MMC™, which is a multimodal resin that comprises a negatively charged 2-(benzoylamino) butanoic acid ligand, at a pH from 4 to 6.2; and eluting the G-CSF at a pH greater than 6.3.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 27, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Gustav Gilljam, Stefan Winge, Maya Tiemeyer
  • Publication number: 20160264619
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Application
    Filed: May 25, 2016
    Publication date: September 15, 2016
    Applicant: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Publication number: 20160256555
    Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Applicant: OCTAPHARMA AG
    Inventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irène Agerkvist
  • Patent number: 9388402
    Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: July 12, 2016
    Assignee: Octapharma AG
    Inventor: Stefan Winge
  • Publication number: 20160177362
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Application
    Filed: February 1, 2016
    Publication date: June 23, 2016
    Applicant: Octapharma AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Patent number: 9371355
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 21, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Patent number: 9296799
    Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: March 29, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
  • Publication number: 20150250879
    Abstract: A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to ?0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 10, 2015
    Applicant: OCTAPHARMA AG
    Inventors: Andrea Heger, Tor-Einar Svae, Juergen Roemisch, Alfred Zoechling
  • Patent number: 9120873
    Abstract: A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Gal?-3Gal.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: September 1, 2015
    Assignee: Octapharma AG
    Inventors: Helena Sandberg, Peter Stenlund, Carola Schröder, Elisabeth Casademunt, Maya Tiemeyer
  • Patent number: 9115381
    Abstract: A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor VIII (rFVIII) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 ?M CaCl2, at least a non-ionic detergent and other nutrient components needed for the cells to grow and produce rFVIII, the cell suspension is cultured under conditions inducing a shear stress mechanically to the eucaryotic cell suspension by adding a power density of at least 3 W/m3.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: August 25, 2015
    Assignee: Octapharma AG
    Inventors: Peter Aizawa, Irene Agerkvist
  • Publication number: 20150211064
    Abstract: A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.
    Type: Application
    Filed: June 6, 2012
    Publication date: July 30, 2015
    Applicant: OCTAPHARMA AG
    Inventors: Stefan Meuer, Thomas Geise, Christian Jacobi, Stefan Haag, Juergen Roemisch
  • Patent number: 8962813
    Abstract: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-?), Transforming growth factor beta (TGF-?), insulin like growth factor (IGF-I) and Fibroblast growth factor (FGF) from sources, such as blood, containing the factor for supporting wound healing, wherein the manufacturing process comprises purification steps which are performed in the presence of antithrombin III (AT-III).
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: February 24, 2015
    Assignee: Octapharma AG
    Inventors: Andrea Neisser-Svae, Stefan Winge, Anna Mjärdestam
  • Publication number: 20150044720
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Application
    Filed: October 3, 2014
    Publication date: February 12, 2015
    Applicant: Octapharma AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Patent number: 8871439
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: October 28, 2014
    Assignee: Octapharma AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Patent number: 8809510
    Abstract: A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 19, 2014
    Assignee: Octapharma AG
    Inventors: Hubert Brandstaetter, Petra Schulz, Juergen Roemisch
  • Publication number: 20140221290
    Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
    Type: Application
    Filed: April 4, 2014
    Publication date: August 7, 2014
    Applicant: OCTAPHARMA AG
    Inventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irene Agerkvist
  • Patent number: 8769841
    Abstract: A process of freeze drying of an essentially aqueous solution comprising at least one first step having a first temperature and pressure level (i.e. primary drying phase) and at least one second step having a second temperature and pressure level (i.e. secondary drying phase) following the first step, wherein in the secondary drying phase limited desorption energy input is applied.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: July 8, 2014
    Assignee: Octapharma AG
    Inventors: Gerhard Gruber, Anton Reschny